The TRAVERSE Trial Changed Everything: TRT and Heart Risk Finally Have an Answer

For over a decade, the question "Is TRT safe for my heart?" had no definitive answer. A 2010 trial was stopped early due to cardiac events in the testosterone group. A 2013 observational study found increased heart attack risk. The FDA slapped a black box warning on all testosterone products in 2015. Men and their doctors were left in limbo.

Then came TRAVERSE — and the answer was clear.

What TRAVERSE Was

The Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial was a randomized, double-blind, placebo-controlled study of 5,246 men aged 45-80 with hypogonadism and established or high risk for cardiovascular disease. It ran for a mean of 33 months — making it by far the largest and longest TRT safety trial ever conducted.

This wasn't a study of healthy men. TRAVERSE specifically enrolled men at elevated cardiovascular risk — the exact population where any cardiac danger from TRT would be most visible.

What TRAVERSE Found

The primary endpoint — major adverse cardiovascular events (MACE: heart attack, stroke, or cardiovascular death) — occurred in 7.0% of the testosterone group and 7.3% of the placebo group. The difference was not statistically significant. TRT did not increase cardiovascular risk.

This finding was published in the New England Journal of Medicine in 2023 and fundamentally shifted the risk-benefit conversation around TRT. The FDA has acknowledged the data, and while the black box warning remains as of 2026, clinical practice has evolved significantly based on this evidence.

What TRAVERSE Did Find

TRAVERSE wasn't entirely neutral on all outcomes. The testosterone group showed a higher incidence of atrial fibrillation, deep vein thrombosis, pulmonary embolism, and acute kidney injury. These signals don't negate the cardiovascular safety finding, but they reinforce that TRT is a medical treatment with real physiological effects that require monitoring.

The study also confirmed TRT's benefits: improved sexual function, physical function, mood, and bone mineral density compared to placebo.

What This Means for Your Decision

TRAVERSE removed the largest cloud hanging over TRT. If you have genuine hypogonadism with symptoms, the cardiovascular risk that previously made many doctors hesitant to prescribe has been addressed by the best evidence available. TRT is not risk-free — no hormone therapy is — but the specific fear that it causes heart attacks has been definitively addressed.